{
    "clinical_study": {
        "@rank": "77141", 
        "arm_group": [
            {
                "arm_group_label": "Ceftazidime plus placebo", 
                "arm_group_type": "Experimental", 
                "description": "2 g i.v. once daily 30 minutes prior to procedure Intervention ERCP plus glycerin suppository as placebo"
            }, 
            {
                "arm_group_label": "Diclophenac sodium plus placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "100 mg suppositories, once daily immediately prior to procedure Intervention ERCP plus 100 ml of saline as placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Diclophenac potassium and ceftazidime are commercially available drugs that are used in\n      various clinical situations. They are safe and known for years. Diclophenac potassium and\n      Ceftazidime have been used in some studies for the prophylaxis and treatment of pancreatitis\n      and Post-ERCP Pancreatitis (PEP). Diclophenac potassium, together with indometacin is\n      currently standard treatment for prevention of (PEP) while ceftazidime is possible\n      alternative treatment for patients with contraindications for nonsteroidal medicines. The\n      aim of the study is to evaluate the efficacy of Ceftazidime for the prophylaxis of PEP."
        }, 
        "brief_title": "Post ERCP Pancreatitis Prevention in Average Risk Patients", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatitis", 
        "condition_browse": {
            "mesh_term": "Pancreatitis"
        }, 
        "detailed_description": {
            "textblock": "Study type:\n\n      Interventional Allocation: Randomized Endpoint Classification: Efficacy Study Intervention\n      Model: Parallel Assignment Masking: only Investigator Primary Purpose: Prevention Study\n      Phase: Phase 4\n\n      Conditions or Focus of the study: Post ERCP pancreatitis\n\n      Intervention information\n\n        -  Intervention Names ERCP\n\n        -  Arm Information\n\n             -  Arm 1:Ceftazidime\n\n             -  Arm 2 (active comparator): Diclophenac potassium"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  o All patients undergone to ERCP irrespectively about the diagnosis\n\n        Exclusion Criteria:\n\n          -  o Unwillingness or inability to consent for the study\n\n               -  Age < 18 years\n\n               -  Previous ERCP (papillotomy)\n\n               -  Intrauterine pregnancy\n\n               -  Breast feeding mother\n\n               -  Allergy to Aspirin or NSAIDs and Ceftazidime\n\n               -  NSAID use within 1 week (ASA 325 mg daily or less acceptable)\n\n               -  Renal failure (Cr > 1.4)\n\n               -  Active or recent (within 4 weeks) gastrointestinal hemorrhage\n\n               -  Existing acute pancreatitis (lipase peak) within 72 hours prior to ERCP\n\n               -  Anticipated inability to follow protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "124", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784445", 
            "org_study_id": "PEP 2013"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ceftazidime plus placebo", 
                "Diclophenac sodium plus placebo"
            ], 
            "description": "Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure", 
            "intervention_name": "Ceftazidime", 
            "intervention_type": "Procedure", 
            "other_name": "Fortaz"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ceftazidime", 
                "Diclofenac"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Endoscopic Retrograde Cholangiopancreatography,", 
        "lastchanged_date": "March 1, 2014", 
        "location": {
            "contact": {
                "email": "ghauser@medri.hr", 
                "last_name": "Goran Hauser, MD, PhD", 
                "phone": "385 98 18 20 726"
            }, 
            "contact_backup": {
                "email": "interna-rijeka@kbc-rijeka.hr", 
                "last_name": "Patricia Mikic, ass", 
                "phone": "385 51 658 122"
            }, 
            "facility": {
                "address": {
                    "city": "Rijeka", 
                    "country": "Croatia", 
                    "state": "Kresimirova 42", 
                    "zip": "51000"
                }, 
                "name": "Clinical Hospital Centre"
            }, 
            "investigator": {
                "last_name": "Goran Hauser, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Croatia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial", 
        "other_outcome": {
            "description": "Influence of PEP severity on time to discharge from hospital", 
            "measure": "Time to discharge from hospital", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Rijeka", 
            "last_name": "Goran Hauser, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Croatia: HALMED (Croatian Agency for Drugs and Medicinal Products)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of PEP in the group of patients receiving Ceftazidime versus incidence of PEP in the group of patients receiving Diclophenac potassium", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784445"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Rijeka", 
            "investigator_full_name": "Goran Hauser", 
            "investigator_title": "Goran Hauser, MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University Hospital Rijeka", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital Rijeka", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}